Related references
Note: Only part of the references are listed.Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease
C. J. M. Williams et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Comparative Effectiveness of Infliximab and Adalimumab for Crohn's Disease
Mark T. Osterman et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Inflammatory Bowel Disease Is Associated With an Increased Risk of Melanoma: A Systematic Review and Meta-analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease
Grace K. H. Choi et al.
JOURNAL OF CROHNS & COLITIS (2014)
Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease
Grace K. H. Choi et al.
JOURNAL OF CROHNS & COLITIS (2014)
Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings
Kristian Thorlund et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Adalimumab and Infliximab Are Equally Effective for Crohn's Disease in Patients Not Previously Treated With Anti-Tumor Necrosis Factor-α Agents
Christine Kestens et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
Gert Van Assche et al.
GUT (2012)
Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)
Daniel A. Sussman et al.
INFLAMMATORY BOWEL DISEASES (2012)
Sample size and power considerations in network meta-analysis
Kristian Thorlund et al.
SYSTEMATIC REVIEWS (2012)
Anti-Tumor Necrosis Factor-alpha Antibodies Induce Regulatory Macrophages in an Fc Region-Dependent Manner
Anne Christine W. Vos et al.
GASTROENTEROLOGY (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Systematic review: the costs of ulcerative colitis in Western countries
R. D. Cohen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study)
Salvatore Scarpato et al.
RHEUMATOLOGY (2010)
Comparison of Drug Retention Rates and Causes of Drug Discontinuation Between Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis
Sophie Martin Du Pan et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
Zehra Kaymakcalan et al.
CLINICAL IMMUNOLOGY (2009)
Voting with Their Feet (VWF) Endpoint: A Meta-Analysis of an Alternative Endpoint in Clinical Trials, Using 5-ASA Induction Studies in Ulcerative Colitis
Sujal C. Rangwalla et al.
INFLAMMATORY BOWEL DISEASES (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews
Fujian Song et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease
Sara Renna et al.
GASTROENTEROLOGY (2008)
Treatment choices, preferences and decision-making by patients with rheumatoid arthritis
Frances Chilton et al.
MUSCULOSKELETAL CARE (2008)
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor at agents
Andrew Nesbitt et al.
INFLAMMATORY BOWEL DISEASES (2007)
Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2007)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study
A Bassi et al.
GUT (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis:: a randomised controlled trial
CSJ Probert et al.
GUT (2003)
Share Paper
